Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 3Congenital Abnormalities 3Urinary Bladder Neoplasms 1Small Cell Lung Carcinoma 1Myelodysplastic Syndromes 1Lymphoma 1Leukemia, Myelomonocytic, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1Blast Crisis 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 160Rituximab 82Peripheral Blood Stem Cell Transplantation 78fludarabine phosphate 75Etoposide 69Filgrastim 67Methotrexate 59Cytarabine 58Vincristine 50Mycophenolic Acid 50Whole-Body Irradiation 48Radiotherapy 43Cyclosporine 43Busulfan 42Tacrolimus 40Melphalan 39Dexamethasone 37Prednisone 36Doxorubicin 36Antilymphocyte Serum 36fludarabine 31blinatumomab 27Methylprednisolone 24Granulocyte Colony-Stimulating Factor 22Carmustine 22Cord Blood Stem Cell Transplantation 21Calcium Dobesilate 18CT-P10 18Inotuzumab Ozogamicin 16sargramostim 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Burkitt Lymphoma × Podophyllotoxin × Clear all
NCT00392990 2019-10-15

Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma

Northwestern University

Phase 2 Completed
25 enrolled 16 charts
Lymphoid

Burkitt Lymphoma, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡